 Home > Active Ingredient News > Drugs Articles > Obtained FDA approval two and a half months ahead of schedule for multi-kinase inhibitors to obtain new indications

Obtained FDA approval two and a half months ahead of schedule for multi-kinase inhibitors to obtain new indications

 Last Update: 2021-10-01
 Source: Internet
 Author: User

Tags

immunotherapy cancer

discovery 3

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Exelixis announced today that the US FDA has approved cabozantinib (cabozantinib, English trade name Cabometyx) for extended indications for the treatment of locally advanced or metastatic differentiated thyroid cancer (DTC) adults and children over 12 years of age
.

These patients progressed after receiving VEGFR-targeted therapy, and were not suitable for radioiodine therapy or developed resistance to it

For this indication, Cabometyx has obtained breakthrough therapy designation and priority review qualifications, and the approval time was more than two months earlier than the target PDUFA day (December 4)
.

Cabozantinib is an oral small molecule tyrosine kinase inhibitor that can inhibit the activities of c-Met, VEGFR2, and AXL and RET
.

This approval is based on the positive results obtained from the pivotal Phase 3 clinical trial COSMIC-311
.

At a median follow-up of 10.

Cancerous thyroid tumors include differentiated, medullary, and undifferentiated types.
Differentiated thyroid tumors account for about 90% of cases, including papillary, follicular, and Hürthle cell carcinomas
.

The standard treatment for differentiated thyroid cancer is surgery first, followed by ablation of the remaining thyroid tissue with radioactive iodine, but about 5% to 15% of patients show resistance to radioactive iodine therapy

Reference materials:

[1] Exelixis Announces US FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer.

[1] Exelixis Announces US FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Retrieved September 17.
2021.
from https:// en

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$49-62/KG FOB

Safe Delivery Freeze Dried Peptides Raw Powder Weight Loss Tirze Peptide Sema 5mg 10mg

CAS No.: 2023788-19-2

Pharmacy Grade

$120.00/UNIT FOB

Hot Sale 1-Adamantanamine Hydrochloride /1-Adamantanamine HCl CAS 665-66-7

CAS No.: 665-66-7

Pharmacy Grade

$20-25/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.